These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Modification of substrate-inhibitor affinities of human platelet monoamine oxidase B in vitro. Szutowicz A, Tomaszewicz M, Orsulak PJ. J Biol Chem; 1989 Oct 25; 264(30):17660-4. PubMed ID: 2509446 [Abstract] [Full Text] [Related]
3. Evidence for existence of A and B form monoamine oxidase in mitochondria from dog platelets. Obata T, Egashira T, Yamanaka Y. Jpn J Pharmacol; 1987 Jun 25; 44(2):105-11. PubMed ID: 3116304 [Abstract] [Full Text] [Related]
5. The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Salach JI, Detmer K, Youdim MB. Mol Pharmacol; 1979 Jul 25; 16(1):234-41. PubMed ID: 481419 [No Abstract] [Full Text] [Related]
7. Dose regimen of deprenyl (selegiline) and platelet MAO activities. Oreland L, Johansson F, Ekstedt J. Acta Neurol Scand Suppl; 1983 Jul 25; 95():87-9. PubMed ID: 6428150 [Abstract] [Full Text] [Related]
8. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl. Arnett CD, Fowler JS, MacGregor RR, Schlyer DJ, Wolf AP, Långström B, Halldin C. J Neurochem; 1987 Aug 25; 49(2):522-7. PubMed ID: 3110375 [Abstract] [Full Text] [Related]
9. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use. Simpson GM, Frederickson E, Palmer R, Pi E, Sloane RB, White K. Biol Psychiatry; 1985 Jun 25; 20(6):684-7. PubMed ID: 3922441 [No Abstract] [Full Text] [Related]
12. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. Riederer P, Youdim MB, Birkmayer W, Jellinger K. Adv Biochem Psychopharmacol; 1978 Jun 25; 19():377-82. PubMed ID: 696465 [No Abstract] [Full Text] [Related]
13. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. Knoll J. J Neural Transm; 1978 Jun 25; 43(3-4):177-98. PubMed ID: 745011 [No Abstract] [Full Text] [Related]
14. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. Lee DH, Mendoza M, Dvorozniak MT, Chung E, van Woert MH, Yahr MD. J Neural Transm Park Dis Dement Sect; 1989 Jun 25; 1(3):189-94. PubMed ID: 2505797 [Abstract] [Full Text] [Related]
15. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease. Youdim MB. J Neural Transm Suppl; 1986 Jun 25; 22():91-105. PubMed ID: 3097263 [Abstract] [Full Text] [Related]
16. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Zsilla G, Földi P, Held G, Székely AM, Knoll J. Pol J Pharmacol Pharm; 1986 Jun 25; 38(1):57-67. PubMed ID: 3020531 [Abstract] [Full Text] [Related]
18. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Mann J, Gershon S. Life Sci; 1980 Mar 17; 26(11):877-82. PubMed ID: 6768943 [No Abstract] [Full Text] [Related]
19. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl]. Severina IS. Biokhimiia; 1979 Feb 17; 44(2):195-207. PubMed ID: 435561 [Abstract] [Full Text] [Related]